Alma vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health network connecting clients to in-network therapists; handles credentialing, billing, and insurance contracting for affiliated clinicians; one of largest US therapist networks.
About
Alma is a New York-based mental health company that operates a network of therapists and psychiatrists, providing them with the business infrastructure to run private practices while accepting insurance. Alma handles credentialing, billing, insurance contracting, and administrative tasks for affiliated clinicians, enabling therapists to focus on patient care rather than paperwork while earning more than they could through employment at a group practice. On the patient side, Alma makes it easier to find available in-network therapists — a persistent challenge in mental healthcare — through its searchable directory of affiliated providers across the country. Alma has built one of the largest networks of private practice therapists accepting insurance in the United States, with thousands of clinicians across most states. Founded in 2017, Alma raised over $220M from investors including Insight Partners, Tiger Global, and Optum Ventures. The company addresses both sides of the mental health access crisis: insufficient supply of providers and inadequate insurance reimbursement making private practice financially unviable.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.